7 recruiting, 7 unknown, 4 not yet recruiting, 3 completed. 24 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Recruiting 7, Unknown 7, Not yet recruiting 4, Completed 3, Active not recruiting 2, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Locally Advanced Cervical Cancer: new trials by email Literature Review of Locally Advanced Cervical Cancer trials Research Report on Locally Advanced Cervical Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Perioperative Adebrelimab for Locally Advanced Cervical Cancer Adebrelimab, Paclitaxel, Cisplatin - Locally Advanced Cervical Cancer | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 35 | 2026-10-01 | 2026-09-10 |
| Cadonilimab Combined With RT in LACC Patients Ineligible for CCRT Cadonilimab, RT - Locally Advanced Cervical Cancer | Phase 2 | Not yet recruiting | Ruijin Hospital | 45 | 2026-03-01 | 2026-03-05 |
| Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer Iparomlimab/Tuvonralimab, nab-paclitaxel, Cisplatin - Locally Advanced Cervical Cancer | Phase 2 | Recruiting | Xijing Hospital | 34 | 2025-09-25 | 2026-10-15 |
| Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC) neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab plus cisplatin,nab-paclitaxel for 1 cycle and Iparomlimab and tuvonralimab for 2 cycles - Locally Advanced Cervical Cancer | Phase 2 | Recruiting | Fujian Cancer Hospital | 43 | 2025-08-21 | 2025-09-11 |
| Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC Neoadjuvant Chemotherapy (NACT) - Locally Advanced Cervical Cancer | Phase 2 | Not yet recruiting | RenJi Hospital | 30 | 2025-04-05 | 2025-04-08 |
| A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) Volrustomig - Locally Advanced Cervical Cancer | Phase 2 | Active not recruiting | AstraZeneca | 37 | 2025-03-31 | 2026-08-18 |
| QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer QL1706+TC - Neoadjuvant Immunotherapy, Locally Advanced Cervical Cancer | Phase 2 | Active not recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 54 | 2025-03-28 | 2026-05-15 |
| Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer Cadonilimab combined with cisplatin - Female, Age ≥ 18 Years Old, No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy | Phase 2 | Recruiting | The First Affiliated Hospital of Zhengzhou University | 29 | 2025-03-10 | 2025-08-05 |
| Neoadjuvant Immunochemotherapy in PD-L1-negative LACC Camrelizumab, Paclitaxel-albumin, Cisplatin - Cervical Cancer, Locally Advanced Cervical Cancer | Phase 2 | Recruiting | Tongji Hospital | 40 | 2024-09-12 | 2025-03-20 |
| Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC Camrelizumab, Cisplatin, Nab paclitaxel - Cervical Cancer, Locally Advanced Cervical Cancer | Phase 2 / Phase 3 | Recruiting | Tongji Hospital | 440 | 2024-04-22 | 2024-10-30 |
| A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer SHR-1316, Cisplatin Injection/Carboplatin Injection, External Beam Radiotherapy (EBRT)/Brachytherapy - Locally Advanced Cervical Cancer | Phase 2 | Unknown | Shanghai Shengdi Pharmaceutical Co., Ltd | 56 | 2024-03-20 | 2024-12-24 |
| Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC Zimberelimab, Albumin-bound Paclitaxel, Cisplatin - Locally Advanced Cervical Cancer | Phase 2 | Recruiting | Tang-Du Hospital | 20 | 2023-10-09 | 2023-09-28 |
| Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer Envafolimab, Cisplatin, External Beam Radiotherapy (EBRT) - Locally Advanced Cervical Cancer | Phase 2 | Not yet recruiting | Chongqing University Cancer Hospital | 36 | 2023-05-01 | 2023-04-05 |
| Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer Cadonilimab（AK104）, EBRT, BT - Locally Advanced Cervical Cancer | Phase 2 | Recruiting | Chongqing University Cancer Hospital | 33 | 2022-12-29 | 2024-09-19 |
| Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer zimberelimab combined With concurrent radiotherapy and chemotherapy - Locally Advanced Cervical Cancer | Phase 2 | Unknown | Shanghai Zhongshan Hospital | 19 | 2022-07-15 | 2022-10-12 |
| PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer Camrelizumab plus Concurrent chemoradiotherapy - Cervical Carcinoma, Chemoradiotherapy | Phase 2 | Unknown | Lei Li | 92 | 2022-03-27 | 2022-04-13 |
| Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer Pembrolizumab, Carboplatin, Taxol - Locally Advanced Cervical Cancer | Phase 2 | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 45 | 2021-02-18 | 2021-08-27 |
| Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer Camrelizumab, radiotherapy, Albumin Paclitaxel - Locally Advanced Cervical Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 40 | 2020-11-01 | 2021-05-13 |
| NAC Followed by RH for the Treatment of LACC Two cycles of neoadjuvant chemotherapy, First imaging evaluation, Second imaging evaluation - Neoadjuvant Chemotherapy, Locally Advanced Cervical Cancer | Phase 2 | Unknown | Lei Li | 60 | 2019-06-19 | 2019-06-20 |
| Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab Atezolizumab, Radiotherapy, Cisplatin - Locally Advanced Cervical Cancer | Phase 2 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 189 | 2018-08-13 | 2026-04-03 |
Showing 20 of 24. Sign in to see all of them.
Uterine Cervical Neoplasms (8) · Neoplasm, Residual (1) · Pathologic Complete Response (1)
Neoplasms (9) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Genital Diseases (8) · Genital Diseases, Female (8) · Genital Neoplasms, Female (8) · Neoplasms by Site (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Uterine Cervical Diseases (8) · Uterine Diseases (8) · Uterine Neoplasms (8) · Disease Attributes (1) · Disease Progression (1) · Neoplastic Processes (1)
Cisplatin (12) · Carboplatin (4) · Paclitaxel (4) · camrelizumab (4) · Brachytherapy (3) · Radiotherapy (3) · Chemoradiotherapy (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Drug Therapy (1) · Neoadjuvant Therapy (1) · Nivolumab (1) · Radiotherapy, Intensity-Modulated (1) · Taxes (1) · atezolizumab (1)
Chongqing University Cancer Hospital (2) · Lei Li (2) · Tongji Hospital (2) · Anhui Provincial Hospital (1) · AstraZeneca (1) · Barts & The London NHS Trust (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Fujian Cancer Hospital (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Institut Curie (1) · People's Hospital of Guangxi Zhuang Autonomous Region (1) · RenJi Hospital (1) · Ruijin Hospital (1) · Shanghai Shengdi Pharmaceutical Co., Ltd (1) · Shanghai Zhongshan Hospital (1)
China (17) · France (2) · Italy (1) · Russia (1) · United Kingdom (1) · United States (1)
Ding Ma (2) · Lei Li, M.D. (2) · Emanuela Romano, MD (1) · Heming Lu, MS (1) · Hongxi Zhao, PhD (1) · Kevin Albuquerque, M.D. (1) · Lin Genlai, MD (1) · Melanie Powell (1) · Qi Zhou, MD (1) · Qi Zhou, PhD (1) · Shujuan Liu, MD (1) · Xie Ya (1) · Yun Mo, MS (1)
PMID 25827291, PMID 25847525, PMID 26568261, PMID 26904570, PMID 27107038, PMID 28840453, PMID 29095678, PMID 29850653, PMID 30659131, PMID 30774597, PMID 30943124, PMID 31188324, PMID 31348579, PMID 31487218, PMID 31812369, PMID 31924334, PMID 33119110, PMID 34534429, PMID 37349318, PMID 41775252
2017 (1)